ISTH 2021 Congress
Hemophilia and Rare Bleeding Disorders » Hemophilia - Basic
Theme Navigation
- ISTH 2021 Congress
- Hemophilia and Rare Bleeding Disorders
- Hemophilia - Basic
- Hemophilia and Rare Bleeding Disorders
-
Abstract Number: PB0491
A Review Following Implemented Training for Health Care Practitioners in Primary Care Settings of Immunisation Practice in Children with Bleeding Disorders
-
Abstract Number: PB0493
Acute Myelogenous Leukemia in a Patient with Mild Haemophilia A. A Case Report at Hospital Infantil de México Federico Gómez
-
Abstract Number: OC 24.4
Altered vWF-FVIII Binding Modulates the Factor VIII Immune Response
-
Abstract Number: PB0481
Analysis of the Percentage of Persons with Severe Hemophilia A as an Indicator of Care
-
Abstract Number: PB0476
Association between Factor VIII Deficiency and Low Bone Mineral Density in Children with Hemophilia
-
Abstract Number: OC 38.3
BAFF Inhibition Prevents FVIII Inhibitor Formation in a Marginal Zone B Cell-independent Manner
-
Abstract Number: OC 49.1
Bone Disease in Hemophilia: The Role of Different Bone Cells
-
Abstract Number: PB0486
Characteristics of Anti-drug Antibody against Emicizumab Analyzed Using Hemophilia A Patient-derived Plasma Samples
-
Abstract Number: PB0473
Clinical Characteristics and Incidence of Inhibitors in Previously Untreated Children with Haemophilia: An Update of the Hemfil Cohort Study
-
Abstract Number: PB0492
Clinical Profile and Bleeding Outcome of Pediatric Hemophilia A: The Royal Hospital’s Experience, Oman
-
Abstract Number: OC 56.2
Comparative Analysis of Residual Factor VIII Expression from Recurrent F8 Nonsense Mutations Indicates that Localization in the B-domain Favours Readthrough-mediated Protein Output
-
Abstract Number: PB0471
Comparative Recovery of FVIII Antigen with Various FVIII Therapeutic Concentrates Using an Improved 2nd Generation ELISA Kit
-
Abstract Number: OC 56.1
Deep Molecular Mechanisms of F8 exon 19 Variants and Translational Approaches in Hemophilia A
-
Abstract Number: PB0477
Differences in Thrombin Generating Capacity in Severe Haemophilia A
-
Abstract Number: PB0469
Dose Selection for Subcutaneous Marzeptacog Alfa (Activated) in Subjects with Factor Vll Deficiency Using Population Pharmacometric Clinical Trial Simulations
-
Abstract Number: PB0458
Dose Selection of Marzeptacog Alfa (Activated) in Children with Hemophilia: A Population Pharmacokinetic Exposure Matching Strategy
-
Abstract Number: PB0467
Effects of von Willebrand Factor on Plasma Haemostasis
-
Abstract Number: PB0482
Evaluation of Primary Haemostasis in Children and Young Adults with Haemophilia
-
Abstract Number: OC 24.1
Evaluation of the Tissue Factor-Independent Mechanism of Action for Eptacog Beta